Objective: Increased thyroid-stimulating hormone (TSH) and FT 3 levels are often found in clinically euthyroid obese individuals. Information on thyroid gene expression in human adipose tissue is scarce. The objective of this study was to measure the expression of the TSH receptor (TSHR) and the thyroid hormone receptor (TRa1) genes in subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese individuals and to test the effect of weight loss on these genes. Study Design and Participants: This study is a prospective study involving 107 obese (body mass index (BMI) ¼ 46±8 kg m À2 , 52 with type 2 diabetes or impaired glucose tolerance) and 12 lean nondiabetic participants. A total of 27 obese patients were restudied 1 year after gastric bypass surgery. Total RNA was extracted from SAT and VAT obtained at baseline from all participants, and from SAT in obese patients post surgery. Results: Circulating TSH and FT 3 levels were 170 and 36%, respectively, higher in obese patients than in controls. In SAT, TSHR and TRa1 were reduced in the obese by 67 and 33%, respectively, regardless of glucose tolerance. A similar trend was found in VAT. Post surgery, a BMI decrease of 33% was associated with a decrease in TSH and FT 3 levels and with a 150 and 70% increase in SAT of TSHR and TRa1, respectively. Conclusion: In both subcutaneous and visceral fat, the thyroid gene expression (especially TSHR) is reduced in obesity. The reversal of these changes with major weight loss and the reciprocal changes in plasma TSH and FT 3 levels suggest a role for adipocytes in the regulation of TSH and thyroid hormones.
Introduction
It is now recognized that thyroid-stimulating hormone (TSH) does not exclusively target the thyroid gland, but also acts on various other tissues, including adipose tissue. 1, 2 On the other hand, it is well known that obesity, especially central obesity, is associated with many hormonal changes. An assessment of thyroid function in severe obesity has shown conflicting results. In a large population study conducted in euthyroid patients from Denmark, 3 the body mass index (BMI) was found to be positively associated with serum TSH and inversely related to free tetraiodotyronine (FT 4 ). This finding has been confirmed in other studies, [4] [5] [6] but not in all. 7 However, in the latter report, study participants were referrals to a thyroid clinic. Furthermore, some studies were carried out in overweight individuals, others included morbidly obese individuals. 5 More recent studies have confirmed that diurnal serum TSH levels are significantly increased, if still within the normal range, in obese individuals, and that major weight loss induces a sizeable reduction in TSH and thyroid hormone levels. [8] [9] [10] It is unknown whether TSH has a role in favoring fat deposition or, on the contrary, whether excessive accumulation of adipose tissue increases TSH secretion. Recent evidence in experimental animals and in humans has shown that adipocytes and preadipocytes possess TSH receptors (TSHRs), [11] [12] [13] and that TSH action induces the differentiation of preadipocytes into adipocytes, adipogenesis and, in children, lipolysis. 11, 14, 15 However, there are no data on the adipose tissue expression of the TSHR gene in conditions such as severe obesity and/or diabetes.
Therefore this study was undertaken (1) to assess the separate role of obesity and type 2 diabetes (T2DM ) in the expression of the thyrotropin receptor (TSHR) and thyroid hormone receptor (a1 subunit, TRa1) genes in visceral adipose tissue (VAT) and in subcutaneous adipose tissue (SAT) and (2) to explore the role of metabolic state and weight loss on receptor expression.
Methods

Participants and study design
The baseline study involved 107 severely obese participants undergoing gastric bypass surgery; 12 non-obese participants undergoing elective abdominal surgery (cholecystectomy) served as the control group. One year after bariatric surgery, 27 patients (14 with normal glucose tolerance (NGT) and 13 with T2DM at baseline) were restudied.
All participants provided informed, written consent, and the protocol was approved by the local Ethics Committee. The obese participants were subgrouped according to their glucose tolerance status (as determined by a standard 75-g oral glucose tolerance test (OGTT) or a previous diagnosis of T2DM): 55 participants had NGT (Ob-NGT), 20 had IGT, that is, impaired glucose tolerance, (Ob-IGT) and 32 had T2DM (Ob-T2DM). All patients were asked to attend our Unit for the metabolic study 2 weeks before surgery; they were also instructed not to exercise for 48 h before the metabolic study or surgery. For the metabolic study, all patients were examined in the morning after an overnight (12-14 h) fast. Peripheral blood samples were obtained for the determination of the lipid profile, plasma glucose, insulin, TSH, FT 3 and FT 4 concentrations. A 75-g OGTT was then performed, with sampling done for every 15 min within the first hour and thereafter for every 30 min for the following 2 h, for measuring levels of plasma glucose and insulin. IGT and diabetes were classified according to the American Diabetes Association (ADA) criteria 16 Diabetic patients who were not taking insulin were considered to have T2DM; insulin-taking diabetic patients whose age at the time of onset was X40 years or whose BMI was 430 kg m À2 were also considered to have T2DM. The remaining insulin-taking diabetic patients were considered to have type 1 diabetes or to be unclassifiable, and were excluded from the study. Anthropometric measurements, height, weight, waist and hip circumferences, as well as systolic and diastolic blood pressure levels were measured as described elsewhere. 17 BMI was calculated as weight divided by height squared, and used as an index of overall adiposity. Patients with a history of binge eating, over consumption of alcohol, smoking, endstage renal disease, cardiac failure, hepatitis B virus or hepatitis C virus chronic hepatitis, thyroid diseases (hypothyroidism or hyperthyroidism, goiter, etc) or receiving thyroid supplementation were excluded from the study. Plasma glucose concentration was measured on a Beckman Glucose Analyzer 2 (Beckman, Fullerton, CA, USA). Fasting concentrations of serum total cholesterol low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides were determined as described elsewhere (Synchron CX4, Beckman Instruments, Inc., Brea, CA, USA). Plasma insulin was measured using a radioimmumoassay (Linco Research, St Charles, MO, USA), and TSH, FT 3 and FT 4 levels were measured using a fully automated immunoenzymometric assay (AIA 600 System, TOSOH Corporation, Tokyo, Japan).
Adipose tissue biopsy samples At baseline, adipose tissue specimens obtained from subcutaneous (SAT) and visceral (VAT) fat depots (2-3 g) were collected during abdominal surgery in RNA-Later (Ambion Inc., Applied Biosystems, Austin, TX, USA), and stored at À20 1C for total RNA extraction. At the follow-up study, a 600-mg adipose tissue specimen was obtained from SAT in a subgroup of 14 Ob-NGT and 13 Ob-T2DM during abdominal remodeling surgery.
Adipocyte isolation
Mature adipocytes were isolated as described by Grohmann et al. 18 The adipose tissue was washed thrice in Hank's balanced salt solution, cut into 1-mm 3 slices and digested with 3 ml of 4 mg ml À1 type II collagenase in Hank's balanced salt solution for 60 min at 37 1C. Fragments of the tissue still remaining after this treatment were removed with forceps. The mature adipocytes were separated from the stromal fraction by centrifugation at 90 Â g for 3 min and were carefully transferred into a sterile Eppendorf tube (Eppendorf, Hamburg, Germany).
Total RNA isolation and cDNA preparation Total RNA was isolated using a mixed protocol: Trizol and RNeasy Midi Kit (Qiagen, Hilden, Germany) to obtain a larger amount of purified RNA that was quantified by measuring absorbance at 260 and 280 nm. RNA integrity was then checked by visual inspection of the two ribosomal RNAs, 18S and 28S, on 1% agarose gel. The average yields of total RNA were 10±1 mg g À1 of the adipose tissue. The isolated RNA was stored at À80 1C until quantification of the target mRNAs. For first-strand cDNA synthesis, 1 mg of total RNA was reverse-transcribed in 20-ml volume using random hexamers as primers, according to the manufacturer's instructions (First strand cDNA Synthesis Kit for reverse transcription (RT)-PCR, AMV, Roche, Indianapolis, IN, USA).
Relative quantification of TSHR; TRa1 gene expression
The relative quantification of mRNAs was performed by real-time PCR using a Light-Cycler instrument (Roche Diagnostics, Mannheim, Germany). Gene-specific primers with a continuous fluorescence acquisition was constructed. To construct standard curves for each gene, total RNA from six control individuals (SAT and VAT) were pooled. In brief, after RNA reverse transcription of the pool sample, the cDNA was diluted into a three-fold serial dilution (1:3-1:27) and both genes (target and reference) were amplified in triplicate. The standard curve was used to assess PCR efficiency. Standard curves were accepted only if the slope for each gene was approximately À3 with an r-value 40.98. Each cDNA was quantified in triplicate. For the relative quantification of samples, the 'Light-Cycler Relative Quantification Software' (Roche Diagnostics, Roche Applied Science, Mannheim, Germany) was used. Results were expressed as the target-reference ratio of each sample, normalized by the target-reference ratio of the calibrator. The calibrator used for each quantification was the sample with a dilution of 10 À3 used in the standard curve. In the present data, the coefficient of variation in measurements for the target gene in each sample was o10%. We used HPRT as the reference gene because its expression was found to be relatively stable in different adipose tissue depots and showed no systematic differences between cases and controls. The mean C t (±s.d.) of HPRT was 25.72±1.42 in obese patients compared with 25.63±1.95 in the control group for SAT, and 25.19 ± 1.24 in obese patients compared with 25.47 ± 1.73 in the control group for VAT.
Protein isolation and western blot analysis for TSHR Adipose tissue biopsy samples (500-800 mg) were collected from six control and six obese individuals and immediately homogenized in complete Ripa lysis buffer 1 Â (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.004 % sodium azide (sc-24948, Santa Cruz Biotechnology, Inc., Heidelberg, Germany) using a Tissue lyser (Qiagen). The homogenate was centrifuged at 500 Â g for 15 min and the infranatant removed and stored at À80 1C. All steps were performed at 4 1C to minimize the risk of proteolysis. The protein assay in each sample was determined using a kit of reagents from BioRad (Hercules, CA, USA). The fifth microgram per lane of total protein was then loaded onto polyacrylamide gels and separated by standard SDS-PAGE (SDS-polyacrylamide gel electrophoresis). Thereafter, the proteins were electrophoretically transferred into the nitrocellulose membrane (Bio-Rad). The blot was blocked overnight in 5% non-fat dried milk at 4 1C in phosphate-buffered solution-T (0.1% Tween-20 in phosphate-buffered solution) and then incubated for 2 h with primary monoclonal antibody against TSHRs (1:500, ab2812, Abcam Inc., Cambridge, MA, USA).
The secondary antibody conjugated to horseradish peroxidase was added at a dilution of 1:3000 (Santa Cruz). Antigenantibody complexes were detected by chemiluminescence using a kit of enhanced chemoluminescence (ECL) reagents (Pierce, Pittsburg, PA, USA) and blots exposed to CL-XPosure films (Pierce). Films were scanned and the optical density of each specific band was analyzed using the Scion image software (Scion Corporation, Frederick, MD, USA). 
Statistical analysis
Results
Baseline study
The clinical characteristics of the study population are reported in Table 1 . The three obese groups generally had similar clinical phenotypes, but blood pressure, serum triglycerides, fasting and 2-h plasma glucose levels, as well as fasting plasma insulin concentrations were higher in patients with T2DM than in NGT patients, whereas IGT patients showed intermediate values. Type 2 diabetic patients were on the following treatment: 67% with metformin and 33% with sulfonylureas; one-third of obese patients, 70% of whom had T2DM, were on antihypertensive treatment (angiotensin-converting enzyme inhibitors, calcium-channel blockers, b-blockers and diuretics).
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Plasma TSH and FT 3 concentrations were significantly higher in association with obesity (by 1.3 mUI ml À1 and 0.8 pg ml À1 on average, Po0.001 and P ¼ 0.01, respectively), whereas FT 4 concentrations were significantly lower (by 2.3 ng ml À1 , P ¼ 0.02), with no independent effect of diabetes (Table 1) . In a multiple regression analysis, a positive correlation was found between plasma TSH and BMI (sd.r ¼ 0.32, P ¼ 0.001) after adjusting for sex, age and fasting plasma glucose.
In the entire dataset, TSHR expression was higher in SAT than in VAT (P ¼ 0.01) ( Table 2) as was its protein expression on western blot (1.70 ± 0.7 vs 1.4 ± 0.6, Po0.05) (Figure 1 In SAT, the expression of TSHR was depressed markedly, and the TRa1 expression tended to be lower, in association with obesity, with no separate effect of diabetes ( Table 2 ).
The protein expression of TSHR was also significantly lower in obese than in control individuals (Figure 1 ). Within this depot, expression levels of TSHR and TRa1 were positively interrelated. In VAT, the TSHR expression was significantly lower in association with obesity, as confirmed by protein expression (Figure 1 ), whereas TRa1 expression did not differ among groups (Table 2) .
In a univariate analysis of the entire dataset, TSHR and TRa1 expressions in VAT were each reciprocally related to BMI (with rho values of À0.28 and À0.21, respectively, Pp0.02). Similarly, in SAT, expression levels were inversely related to BMI (with rho values of À0.20 and À0.32, respectively, Pp0.04). In multivariate models adjusting for sex, age and fasting plasma glucose, TSHR and TRa1 expressions remained significantly associated with BMI in an inverse manner both in SAT and in VAT (with sd.rs ranging from À0.18 to À0.28).
Follow-up study
For the 27 obese patients who underwent gastric bypass surgery (14 with NGT and 13 with diabetes at baseline), the clinical characteristics at baseline and 1 year after surgery are reported in Table 3 . For an average 32% decrease in BMI, all clinical and metabolic parameters were significantly improved, the changes in HbA 1c (hemoglobin A1c) and fasting glucose concentrations being more pronounced in TSH and TH receptors expression in fat depots M Nannipieri et al diabetic than in NGT patients. Plasma TSH and FT 3 concentrations decreased in both groups post surgery, whereas FT 4 concentrations increased (Table 3 ). In SAT, the expression of TSHR and TRa1 each was increased significantly regardless of glucose tolerance status (Table 4) .
Discussion
The major findings of this study are that: (1) the expression levels of TSHR and TRa1 are higher in SAT than in VAT; (2) in both adipose tissue depots, TSHRFand, marginally, TRa1Fis reduced in obesity (and in proportion to the degree of obesity) regardless of the glucose tolerance status; (3) serum TSH and FT 3 concentrations are higher in obese than in lean individuals; and (4) after major weight loss, TSHR and TRa1 expression in SAT increases significantly, with a concomitant reduction in circulating TSH and FT 3 levels. Many previous studies have reported increased TSH and FT 3 levels in obese, clinically euthyroid patients; 3-6 our series confirms these findings. On the other hand, this study is one of the few investigations that have unequivocally shown that weight loss leads to a reduction in both TSH and FT 3 levels. 9, 10, 19, 20 Several explanations have been proposed to account for the influence of obesity on thyroid hormones. One suggests that the increased TSH level could reflect pituitary adaptation to increased adiposity through adipokines. In morbidly obese patients with subclinical hypothyroidism, bariatric surgery led to changes in obesity-related adipokines believed to influence the synthesis and secretion of thyroid hormones. 9, 19 However, in a recent study from our laboratory, 10 the direct relationship between 24-h mean concentrations of TSH and leptin in euthyroid obese patients was lost after adjusting for fat mass, suggesting that other mechanisms modulate TSH concentrations in morbidly obese patients. Another explanation is that the thyroid hormone profile of the obese individuals reflects pituitary resistance to thyroid hormones, with a variable degree of secondary impairment of thyroid hormone peripheral metabolism. 19 It has also been suggested that the impaired control of TSH release by thyroid hormones in obesity may represent an adaptive thermogenic phenomenon. Finally, it is possible that obesity leads to a state of TSH and thyroid hormone resistance in peripheral tissues. 20 However, information on the tissue expression of genes encoding for TSH and thyroid hormone receptors, and activity of the respective proteins in relation to body weight or diabetes is scarce. TSHRs have been found in rats and in human adipose tissues. 21, 22 In the post-neonatal period and in children, an important lipolytic effect of TSH on adipose tissue has been described, rapidly declining with increasing age. 15 Other studies have shown that TSH has a role in the regulation of several adipokines synthetized in mature adipocytes 23, 24, 25 and in the induction of preadipocyte proliferation and differentiation. 26 To our knowledge, this is the first study addressing the expression of TSHR and TRa1 in adipose tissue obtained from obese patients, and evaluating the effect of weight loss on these receptors. The findings, of a reduced expression which reverses with weight loss and those of reciprocal changes in expression and circulating TSH and FT 3 concentrations, suggest a role of obesityFand the expanded adipose mass in particularFin regulating TSHRs and, indirectly, also in circulating TSH, rather than a contribution of thyroid axis to the causation of obesity. Thus, one could speculate that hypertrophy changes the cellular phenotype of the adipocyte, reducing the expression of these receptors in much the same way as with adiponectin receptors 27 or insulin sensitivity. 28 As a consequence of the downregulation in the thyroid hormone and TSHR expression, plasma TSH and FT 3 concentrations could increase to cope with peripheral hormone resistance. This sequence of events would be TSH and TH receptors expression in fat depots M Nannipieri et al reversed by weight loss, which restores the size and function of mature adipocytes. Unfortunately, we could not obtain functional data on the activity of these receptors before and after surgery in adipose tissue, which would support this hypothesis. Further studies determining peripheral indices of thyroid function (thyroid hormone metabolites, deoidinase activity and iodine intake) as well as receptor activity on adipose cells will be required to further characterize the clinical significance of increased TSH and low TSHR in morbidly obese patients. It is of interest that, in our series the presence of diabetes had no effect on the thyroid hormone system independently of obesity. Although a low T 3 syndrome has been reported in some patients with decompensated diabetes, 29 adipose tissue mass has not been taken into account. Our finding relates to relatively well-controlled diabetes, which essentially resolved with major weight loss.
In conclusion, in obese individuals, TSHR is less expressed than in lean individuals in the face of higher plasma TSH levels; both these changes are reversed after major weight loss.
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